User profiles for Jovan Borjan
Jovan BorjanThe University of Texas MD Anderson Cancer Center Verified email at mdanderson.org Cited by 127 |
An Overview of the Treatment of Less Common Non–Lactose‐Fermenting Gram‐Negative Bacteria
HK Spencer, SL Spitznogle, J Borjan… - … : The Journal of …, 2020 - Wiley Online Library
Stenotrophomonas maltophilia, Burkholderia cepacia complex, Elizabethkingia spp.,
Chryseobacterium spp., Achromobacter spp., and Alcaligenes spp. are less‐common non–lactose‐…
Chryseobacterium spp., Achromobacter spp., and Alcaligenes spp. are less‐common non–lactose‐…
Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo …
Ceftazidime-avibactam is used clinically in combination with a polymyxin for the treatment of
carbapenem-resistant Gram-negative infections; however, there are limited data to support …
carbapenem-resistant Gram-negative infections; however, there are limited data to support …
[HTML][HTML] High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients
…, A Knopfelmacher, V Mulanovich, J Borjan… - Frontiers in …, 2021 - frontiersin.org
Background COVID-19 Convalescent plasma (CCP) is safe and effective, particularly if
given at an early stage of the disease. Our study aimed to identify an association between …
given at an early stage of the disease. Our study aimed to identify an association between …
Significant publications on infectious diseases pharmacotherapy in 2018
J Borjan, AJ Gonzales-Luna… - Journal of …, 2019 - journals.sagepub.com
Purpose: To summarize the top 10 most influential peer-reviewed infectious diseases (ID)
pharmacotherapy articles published in the year 2018. Summary: Members of the Houston …
pharmacotherapy articles published in the year 2018. Summary: Members of the Houston …
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period.
Background: An increasing number of observational studies have reported the persistence
of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The …
of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The …
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
…, RF Chemaly, V Mulanovich, J Adachi, J Borjan… - elife, 2023 - elifesciences.org
Background: In this international multicenter study, we aimed to determine the independent
risk factors associated with increased 30 day mortality and the impact of cancer and novel …
risk factors associated with increased 30 day mortality and the impact of cancer and novel …
High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant
Objectives To characterize a bla CMY variant associated with ceftazidime/avibactam
resistance from a serially collected Escherichia coli isolate. Methods A patient with an intra-…
resistance from a serially collected Escherichia coli isolate. Methods A patient with an intra-…
# AMRrounds: a systematic educational approach for navigating bench to bedside antimicrobial resistance
Antimicrobial resistance (AMR) continues to serve as a major global health crisis. Clinicians
practising in this modern era are faced with ongoing challenges in the therapeutic …
practising in this modern era are faced with ongoing challenges in the therapeutic …
Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to
the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an …
the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an …
[PDF][PDF] 2451. Synergistic activity of ceftazidime–avibactam in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae
Methods. A total of 7,037 non-duplicate Eba were collected from UTI, IAI, or LRTI in 26 sites
in 6 countries in LA, as a part of the INFORM surveillance study from 2012 to 2016. …
in 6 countries in LA, as a part of the INFORM surveillance study from 2012 to 2016. …